Chronic Rhinosinusitis (CRS)
Conditions
Interventions
Eosinophilic chronic rhinosinusitis with nasal polyps:None
Non-eosinophilic rhinosinusitis with nasal polyps:None
Chronic rhinosinusitis without nasal polyps:None
Control:None
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Chronic sinusitis group: 1. Meet the diagnostic criteria for CRSwNP in EPOS 2020, voluntarily participate in this study and sign the informed consent form. 1) Chronic sinusitis without polyps (CRSsNP): nasal endoscopy showed no nasal polyps 2) Eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP): nasal polyps on nasal endoscopy with intrinsic type 2 inflammation: A. blood EOS count greater than 0.25×10^9/L or percentage greater than 4.5%; B. Total blood IgE>30 IU/ml; C. SNOT-22 score greater than or equal to 40 points; D. Asthma comorbid with regular inhaled hormone control, E. loss of smell, F. need to use oral glucocorticoids. At least 4 out of 6 must be met. 3) Non-eosinophilic chronic sinusitis with nasal polyps: nasal polyps were found on nasal endoscopy, which did not meet the above diagnostic criteria for type 2 inflammation. Control group: patients with benign and malignant tumors of nasal sinuses, cerebrospinal fluid rhinorrhea and other diseases, and were admitted to the hospital for nasal sinus surgery.
Exclusion criteria
Exclusion criteria: Chronic sinusitis group: Combined with nasal sinus tumors, fungal sinusitis, immunodeficiency diseases, posterior nostril polyps, etc.; History of upper respiratory tract infection within the past 1 month; Age, medication history, surgical history, etc. did not meet the inclusion criteria; Pregnant women or those who are planning to become pregnant in the near future; Unwilling to participate in this study. Control group: nasal sinus tumors invading the uncinate process and ethmoid sinuses; Combined with chronic sinusitis, fungal sinusitis, immunodeficiency diseases, posterior nostril polyps, etc.; History of upper respiratory tract infection within the past 1 month; Age, medication history, surgical history, etc. did not meet the inclusion criteria; Pregnant women or those who are planning to become pregnant in the near future; Unwilling to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| NPS score;CT score;VAS score;SNOT-22 score;Drug dosage;Other relevant therapeutic drugs;Adverse events; | — |
Countries
China
Contacts
Public ContactLyu Wei
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed